Gauri Varadhachary

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Diagnostic strategies for unknown primary cancer
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1776-85. 2004
  2. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
  3. ncbi request reprint Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
    G R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX, 77030 4009, USA
    Int J Clin Oncol 19:479-84. 2014
  4. doi request reprint New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling
    Gauri Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 19:4027-33. 2013
  5. pmc Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
  6. pmc Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
  7. doi request reprint Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:3487-95. 2008
  8. ncbi request reprint Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1035-46. 2006
  9. doi request reprint Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Lancet Oncol 9:596-9. 2008
  10. ncbi request reprint Carcinoma of unknown primary: focused evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Compr Canc Netw 9:1406-12. 2011

Detail Information

Publications42

  1. ncbi request reprint Diagnostic strategies for unknown primary cancer
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1776-85. 2004
    ..The authors discuss the role of histochemical markers in the diagnosis of UPC and the most recent data regarding the use of imaging and invasive diagnostic modalities and gene expression profiles...
  2. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
    ..There is no optimal treatment schema for this distinct stage of disease, so the role of surgery is undefined...
  3. ncbi request reprint Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
    G R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX, 77030 4009, USA
    Int J Clin Oncol 19:479-84. 2014
    ..Carcinoma of unknown primary with a "gastrointestinal profile" is an emerging, favorable entity. Distinguishing this entity is of increasing significance given the progress in the treatment of colorectal cancer...
  4. doi request reprint New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling
    Gauri Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 19:4027-33. 2013
    ....
  5. pmc Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
    ..Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies...
  6. pmc Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
    ..The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models...
  7. doi request reprint Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:3487-95. 2008
    ..We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma...
  8. ncbi request reprint Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1035-46. 2006
    ....
  9. doi request reprint Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Lancet Oncol 9:596-9. 2008
    ..In the era of molecular profiling, we expect that additional work with CCP-CUP and other CUP subsets will provide attractive tailored treatment alternatives, with efficacies that exceed the current one-treatment-fits-all approach...
  10. ncbi request reprint Carcinoma of unknown primary: focused evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Compr Canc Netw 9:1406-12. 2011
    ..Just as physicians need to be selective in their diagnostic approach, they also need to be selective in their research efforts as they continue to impact quality of life and survival for patients with CUP...
  11. ncbi request reprint Gastric cancer
    Gauri Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 3:118-24. 2005
    ..We anticipate that improved trial design, availability of molecular techniques, and continued search for better cytotoxic and targeted agents will help develop better treatments for patients with advanced gastric cancer...
  12. ncbi request reprint Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 70:735-43. 2008
    ..We retrospectively compared treatment outcomes in patients treated with pancreaticoduodenectomy alone versus those who received additional adjuvant CRT...
  13. doi request reprint Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Invest New Drugs 26:445-54. 2008
    ..0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules...
  14. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
    ..We conducted a phase II trial to assess the survival duration and quality of life of patients who received adjuvant interferon-based chemoradiation for pancreatic adenocarcinoma after pancreaticoduodenectomy...
  15. ncbi request reprint Future chemoradiation strategies in pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:335-46. 2007
    ..Herein, we discuss the relative merits of strategies that seek to improve outcome through these novel means and present recent data from novel strategies that will provide the background for future trials...
  16. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
    ..Following potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield...
  17. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
    ..To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma...
  18. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  19. doi request reprint Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5749-56. 2012
    ..In this study, the authors sought to determine the rate at which neoadjuvant therapy is associated with a reduction in the size or stage of borderline resectable tumors...
  20. doi request reprint The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Mohamed A Khalil
    M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Invest New Drugs 31:1375-83. 2013
    ..72). In conclusion, though there was a trend towards improved survival with the addition of erlotinib to gemcitabine and cisplatin, this does not reach statistical significance...
  21. ncbi request reprint The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Best Pract Res Clin Gastroenterol 20:365-82. 2006
    ..Herein, we discuss the rationale for the use of pre-operative chemoradiation in pancreatic cancer, the results of treatment, and future strategies to address the pattern of disease recurrence...
  22. ncbi request reprint Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2589-96. 2006
    ..Prognostic factors are inadequately defined for disease-free survival and overall survival in patients with LAPC who are receiving chemoradiation, so more definitive prognostic factors would be very useful for designing clinical trials...
  23. ncbi request reprint Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer
    Hop S Tran Cao
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, FCT 17 6058, Houston, TX, 77230 1402, USA
    J Gastrointest Surg 18:269-78; discussion 278. 2014
    ..We assessed the ability of radiographic criteria to predict the need for superior mesenteric-portal vein (SMV-PV) resection and the presence of histologic vein invasion...
  24. pmc Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation
    Cielito C Reyes-Gibby
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Pain Symptom Manage 34:244-52. 2007
    ..This study demonstrates the feasibility and usefulness of symptom assessment in chemoradiation protocols. Future studies with larger cohorts are needed to further characterize multiple symptoms associated with chemoradiation...
  25. doi request reprint Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors
    Michael J Overman
    University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Invest 26:794-9. 2008
    ..No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population...
  26. ncbi request reprint Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?
    Thomas A Aloia
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 204:347-55. 2007
    ..This study reexamined the frequency of delayed recovery and assessed other factors associated with adjuvant therapy administration after PD at a high-volume center...
  27. pmc Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e65144. 2013
    ..We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas of the pancreas, bile duct, and duodenum by gene expression analysis...
  28. ncbi request reprint Preoperative and adjuvant therapies for upper gastrointestinal cancers
    Gauri Varadhachary
    MD Anderson Cancer Center, GI Medical Oncology Department, University of Texas, 1515 Holcombe Boulevard, Mailbox 426, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 5:719-25. 2005
    ..The role of molecular profiling is evolving and will help us differentiate the responders from the nonresponders...
  29. doi request reprint Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 27:2598-603. 2009
    ..We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin...
  30. ncbi request reprint Metastatic patterns in adenocarcinoma
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer 106:1624-33. 2006
    ..The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns...
  31. doi request reprint Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
    Douglas B Evans
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:3496-502. 2008
    ..We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma...
  32. ncbi request reprint Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases
    Gerald S Falchook
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 108:515-9. 2008
    ..The purpose of this study is to define the clinical characteristics and treatment strategies for this patient population...
  33. doi request reprint Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress
    Robert A Wolff
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA
    Ann Surg Oncol 15:2773-86. 2008
    ..A critical analysis of completed adjuvant trials will be provided and a framework for the conduct of future trials of adjuvant therapy proposed...
  34. ncbi request reprint Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 110:47-55. 2007
    ....
  35. pmc Gastric adenocarcinoma in children and adolescents
    Vivek Subbiah
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Pediatr Blood Cancer 57:524-7. 2011
    ..Initial chemotherapy was mainly platinum-based. Median time to progression was 4 months. The only long-term survivor was a patient with localized disease who had complete surgical removal of primary tumor...
  36. ncbi request reprint Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 32:S40-2. 2005
    ..New and promising targeted and cytotoxic therapies are currently being studied and will ideally continue to extend the median survival as well as improve the quality of life of patients with colorectal cancer...
  37. doi request reprint Management of borderline resectable pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Semin Radiat Oncol 24:105-12. 2014
    ..The rationale for and results following treatment with neoadjuvant chemotherapy and chemoradiation and subsequent surgical resection of the primary tumor are described in detail and existing data are reviewed. ..
  38. ncbi request reprint Current management of borderline-resectable pancreatic cancer
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Adv Hematol Oncol 5:765-7. 2007
  39. doi request reprint Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4442-8. 2008
    ..To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site...
  40. ncbi request reprint Phase I trial of oral talactoferrin alfa in refractory solid tumors
    Teresa G Hayes
    Michael E DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA
    Invest New Drugs 24:233-40. 2006
    ..The purpose of the present study was to evaluate the safety and tolerability of talactoferrin alfa (talactoferrin; TLF) in humans, as well as pharmacokinetics and pharmacodynamics...
  41. doi request reprint Overview of patient management and future directions in unknown primary carcinoma
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 36:75-80. 2009
    ....
  42. doi request reprint Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
    Henry Q Xiong
    Center for Cancer and Blood Disorders, Fort Worth, Texas, USA
    Cancer 113:2046-52. 2008
    ..A phase 2 trial was conducted to explore the efficacy of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer previously who were treated with gemcitabine...